Virbac SA (VRBCF)
- GlobeNewswire
VIRBAC: Building on the momentum of the second half of 2023, strong first-quarter revenue growth of +10.8% at constant exchange rates
KEY FIGURESRevenue1st quarter 2024 €345.7MGrowth at constant exchange rates and scope1 +9.7% of which companion animals +16.2%farm animals +1.2%Growth at constant exchange rates +10.8% Overall change +9.8% 1growth at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the exchange rate
- GlobeNewswire
Virbac : Declaration of the number of shares and voting rights 03/2024
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsMarch, 31 20248 458 000Gross total of voting rights : 12 780 944Net total* of vo
- GlobeNewswire
Virbac acquired Sasaeah, a leading animal health player in Japan
On April 1, we successfully completed the acquisition of Sasaeah. This strategic acquisition brings Virbac a leadership position in the farm animal vaccines market in Japan, notably in the cattle segment, and a large portfolio of pharmaceutical products for all the major species. Formed through the combination of two legacy animal health providers (Fujita Pharmaceutical Co. Ltd. and Kyoto Biken Laboratories Inc.) under the stewardship of ORIX Corporation, Sasaeah generates annual revenues of abo
